Comparative Study of Vaginal versus Intramuscular Progesterone in the Prevention of Preterm Delivery
A Randomized Clinical Trial
Keywords:
pregnancy, preterm delivery, progestinsAbstract
Background: Preterm birth is a worldwide health concern due to its various negative consequences. Therefore, the prevention of preterm birth is a top priority for healthcare systems in all countries.
Objective: To compare the effectiveness of vaginal versus intramuscular progesterone in the prevention of preterm delivery.
Methods: This randomized clinical trial was conducted at Shahid Sadoughi Hospital in Yazd, Iran, from November 21, 2012 to January 20, 2015. Seventy-eight pregnant women with singleton pregnancy and one risk factor of preterm delivery were included in the study. The subjects were assigned randomly to two groups, with group one receiving Cyclogest and group two receiving 17-α hydroxyprogesterone caproate. Subsequently, we analyzed drug complications during pregnancy, delivery time, neonatal outcomes, and patients' satisfaction among the two groups. The data were analyzed using SPSS version 16. We used descriptive statistics, chi-squared, t-test, and ANOVA for the analyses of primary and secondary outcomes.
Results: Among the 39 births in group one, 33.3% occurred preterm, and, among the 39 births in group two, 30.7% occurred preterm (< 37 weeks). The mean gestational ages at delivery in groups 1 and 2 were 37.07 ± 2.23 and 36.81 ± 2.77 weeks, respectively (p = 0.765). Other variables were not significantly different between the two groups, including birth weight (p = 0.745), Apgar scores for the first and fifth minutes (p = 0.574, 0.630), length of stay in the neonatal intensive care unit (NICU) when the newborns needed hospitalization (p = 0.358), and the patients' satisfaction with the drugs that were used (p = 0.615).
Conclusions: In this study, vaginal progesterone and intramuscular progesterone had the same levels of effectiveness, safety and acceptance by patients in the prevention of preterm delivery. Therefore, both can be used for this purpose in clinical practices, but more studies are needed.
Trial registration: The trial was registered at the Iranian Registry of Clinical Trials (http://www.irct.ir) with the Irct ID: IRCT2015040921670N1.
Funding: The authors received no financial support for the research, authorship, and/or publication of this article.
References
Bernstein P, Berck D, Burgess T, Dayal A, Einstein F, Florio Ph, et al. Preventing preterm birth: The role
of 17 α hydroxyprogeterone caproate. ACOG District II: 2009.
Dodd JM, Crowther CA. The role of progesterone in prevention of preterm birth. Int J Womens Health
; 1: 73–84. PMCID: PMC2971700.
Khandelwal M. Vaginal progesterone in risk reduction of preterm birth in women with short cervix in the
midtrimester of pregnancy. Int J Womens Health 2012; 4: 481–490. doi: 10.2147/IJWH.S28944, PMCID:
PMC3469232.
Cooper RL. Is there enough evidence to support the use of 17 Alpha-Hydroxyprogesterone Caproate in
preventing preterm labor in healthy women who have had a prior preterm delivery?. IJAPA 2010; 7(2).
(open access)
Regmi MC, Rijal P, Agrawal A, Uprety D. Progesterone for Prevention of Recurrent Preterm Labor after
Arrested Preterm Labor: A Randomized Controlled Trial. Gynecol Obstet 2012; 2(4). (open access). doi:
4172/2161-0932.1000125.
Farine D, Mundle WR, Dodd J. The Use of Progesterone for Prevention of Preterm Birth. JOGC 2008; 202;
-72. PMID: 18198071.
Nisha S, Uma S, Shikha S. Comparative Study of Nifedipine and Isoxpurine as Tocolytics for Preterm
Labor. Journal Obstets & Gynecol India (September–October 2011); 61(5): 512–515. doi:
1007/s13224-011-0080-1, PMCID: PMC3257331.
Abd El Hameed AA. Vaginal versus intramuscular progesterone in the prevention of preterm labor and
their effect on uterine and fetal blood flow. Middle East Fertility Society Journal 2012; 17: 163–169.
doi:10.1016/j.mefs.2011.12.003.
Da Fonseca EB, Bittar RE, Carvalho MH, Zugaib M. Prophylactic administration of progesterone by
vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a
randomized placebo-controlled double-blind study. Am J Obstet Gynecol 2003; 188: 419-24. PMID:
El-Gharib MN, El-Hawary TM. Matched sample comparison of intramuscular versus vaginal micronized
progesterone for prevention of preterm birth. J Matern Fetal Neonatal Med. 2013; 26(7): 716-9. doi:
3109/14767058.2012.755165, PMID: 23205864.
Maher MA, Abdelaziz A, Ellaithy M, Bazeed MF. Prevention of preterm birth: a randomized trial of
vaginal compared with intramuscular progesterone. Acta Obstet Gynecol Scand. 2013; 92(2): 215-22. doi:
1111/aogs.12017, PMID: 23016508.
Velez Edwards DR, Likis FE, Andrews JC, Woodworth AL, Jerome RN, Fonnesbeck CJ, et al.
Progestogens for preterm birth prevention: a systematic review and meta-analysis by drug route. Arch
Gynecol Obstet. 2013; 287(6): 1059-66. doi: 10.1007/s00404-013-2789-9, PMID: 23532387.
Hassan SS, Romero R, Vidyadhari D, Fusey S, Baxter JK, Khandelwal M, et al. Vaginal progesterone
reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized,
double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol. 2011; 38(1): 18-31. doi:
1002/uog.9017, PMID: 21472815.
O'Brien JM, Adair CD, Lewis DF, Hall DR, Defranco EA, Fusey S, et al. Progesterone vaginal gel for the
reduction of recurrent preterm birth: primary results from a randomized, double-blind, placebo-controlled
trial. Ultrasound Obstet Gynecol. 2007; 30(5): 687-96. PMID: 17899572.
Check JH, Rankin A, Teichman M. The risk of fetal anomalies as a result of progesterone therapy during
pregnancy. Fertil Steril 1986; 45: 575–7. PMID: 3956772.
Katz Z, Lancet M, Skornik J, Chemke J, Mogilner BM, Klinberg M. Teratogenicity of progestogens given
during the first trimester of pregnancy. Obstet Gynecol 1985; 65: 775–80. PMID: 3158848.
Kester PA. Effects of prenatally administered 17 alphahydroxyprogesterone caproate in adolescent males.
Arch Sex Behav 1984; 13: 441–55. PMID: 6517685.
Saleh Gargari S, Habibolahi M, Zonobi Z, Khani Z, Sadat Sarfjoo F, Kazemi Robati A, et al. Outcome of
Vaginal Progesterone as a Tocolytic Agent: Randomized Clinical Trial. ISRN Obstetrics and Gynecology
; Article ID 607906, 5 pages doi:10.5402/2012/607906, PMID: 22685670, PMCID: PMC3366248.
Bomba-Opon DA, Kosinska-Kaczynska K, Kosinski P, Wegrzyn P, Kaczynski B, Wielgos M. Vaginal
progesterone after tocolytic therapy in threatened preterm labor. J Matern Fetal Neonatal Med. 2012; 25(7):
-9. doi: 10.3109/14767058.2011.629014, PMID: 21967664.
Dudas I, Gidai J, Czeizel AE. Population-based case-control teratogenic study of hydroxyprogesterone
treatment during pregnancy. Congenit Anom 2006; 46(4): 194-8. PMID: 17096820
Dodd JM, Crowther CA, Cincotta R, Flenady V, Robinson JS. Progesterone supplementation for
preventing preterm birth: a systematic review and meta-analysis. Acta Obstet Gynecol Scand 2005; 84:
–533. PMID: 15901258.
Durnwald CP, Lynch CD, Walker H, et al. The effect of treatment with 17 alpha-hydroxyprogesterone
caproate on changes in cervical length over time. Am J Obstet Gynecol. 2009; 201(4): 410 e1-5. doi:
1016/j.ajog.2009.07.009, PMID: 19716117, PMCID: PMC3808191.
DeFranco EA, O'Brien JM, Adair CD, Lewis DF, Hall DR, Fusey S, et al. Vaginal progesterone is
associated with a decrease in risk for early preterm birth and improved neonatal outcome in women with a
short cervix: a secondary analysis from a randomized, double-blind, placebo-controlled trial. Ultrasound
Obstet Gynecol. 2007; 30(5): 697-705. PMID: 17899571.
Conde-Agudelo A, Romero R, Nicolaides K, Chaiworapongsa T, O'Brien JM, Cetingoz E, et al. Vaginal
progesterone vs cervical cerclage for the prevention of preterm birth in women with a sonographic short
cervix, previous preterm birth, and singleton gestation: a systematic review and indirect comparison
metaanalysis. AJOG 2013; 208 (1): 42.e1–42.e18. doi: 10.1016/j.ajog.2012.10.877, PMID: 23157855,
PMCID: PMC3529767.
Berghella V, Figueroa D, Szychowski JM, Owen J, Hankins GD, Iams JD, et al. 17-alpha
hydroxyprogesterone caproate for the prevention of preterm birth in women with prior preterm birth and a
short cervical length. Am J Obstet Gynecol. 2010; 202(4): 351.e1-6. doi: 10.1016/j.ajog.2010.02.019,
PMID: 20350641, PMCID: PMC2855838.
Fonseca EB, Celik E, Parra M, et al. Progesterone and the risk of preterm birth among women with a short
cervix. N Engl J Med. 2007; 357(5): 462-9. PMID: 17671254.
Dodd JM, Flenady VJ, Cincotta R, Crowther CA. Progesterone for the Prevention of Preterm Birth: A
Systematic Review. Obstet Gynecol 2008; 112(1): 127-134. doi: 10.1097/AOG.0b013e31817d0262,
PMID: 18591318.
Published
Issue
Section
License
Copyright (c) 2020 knowledge kingdom publishing
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
